Akorn, Inc. / VPI Holdings Corp. (VersaPharm Incorporated)
2014 · Acquisition/Merger · $440M · Complete
Announcement Sentiment
75
Strongly positive
Akorn agreed to acquire VPI Holdings, parent of VersaPharm, for $440M in cash, adding 11 ANDAs filed with FDA plus a 20+ product pipeline in dermatology, TB and hemophilia. Closed August 12, 2014 with FTC-mandated divestitures.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 10yr post-close.
Key facts
AnnouncedMay 09, 2014
ClosedAug 12, 2014
Deal value$440M
Deal typeAcquisition/Merger
Therapeutic areaSpecialty generics across dermatology, infectious disease, hematology
IndicationsSpecialty generics across dermatology, infectious disease, hematology
Key assetsGeneric dermatology, tuberculosis and hemophilia products